Biochemical and Structural Analysis of the Binding Determinants of a Vascular Endothelial Growth Factor Receptor Peptidic Antagonist

2010 ◽  
Vol 53 (11) ◽  
pp. 4428-4440 ◽  
Author(s):  
Benoit Gautier ◽  
Victor Goncalves ◽  
Donatella Diana ◽  
Rossella Di Stasi ◽  
Florence Teillet ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Structural Analysis ◽  
Growth Factor ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Binding Determinants

Structural analysis of vascular endothelial growth factor receptor‐2/ligand complexes by small‐angle X‐ray solution scattering

2011 ◽  
Vol 25 (9) ◽  
pp. 2980-2986 ◽  
Author(s):  
Kaisa Kisko ◽  
Maurice S. Brozzo ◽  
John Missimer ◽  
Thomas Schleier ◽  
Andreas Menzel ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Structural Analysis ◽  
Growth Factor ◽  
Small Angle ◽  
Growth Factor Receptor ◽  
Vascular Endothelial ◽  
X Ray ◽  
Endothelial Growth Factor

Fortgeschrittenes medulläres Schilddrüsenkarzinom: Vandetanib verbessert das progressionsfreie Überleben

2012 ◽  
Vol 03 (02) ◽  
pp. 93-92
Author(s):  
Alexander Kretzschmar
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Growth Factor Receptor ◽  
Phase Iii ◽  
Vascular Endothelial ◽  
Medulläres Schilddrüsenkarzinom ◽  
Epidermal Growth ◽  
Endothelial Growth Factor

Vandetanib ist ein oraler Hemmer des RET-Kinase-, VEGF (Vascular Endothelial Growth Factor Receptor)- und EGFR (Epidermal Growth Factor Receptor)-Signalwegs. In einer zulassungsrelevanten, randomisierten, doppelblinden, placebokontrollierten Phase- III-Studie verlängerte der Tyrosinkinasehemmer das progressionsfreie Überleben (PFS) signifikant länger als Placebo.

Sign in / Sign up

Export Citation Format

Share Document